अमूर्त

Design, development and evaluation of ketotifen fumarate solid lipid nanoparticles.

Reshma NC

The aim of the present study is to develop Ketotifen Fumarate solid lipid nanoparticles and to evaluate them. Formulations were formulated by using three lipids at various proportions. Solid lipid nanoparticles were prepared by hot homogenization followed by ultra-sonicationtechnique. The nanoparticles were evaluated Suitable lipids (Triastearin, GMS and Compritol), stabilizer (Soy lecithin) and surfactant (Poloxamer) were selected. FT-IR studies were carried to check drug-excipient compatibility. In the present study nine studies, release kinetics for particle size, PDI, zeta potential Drug content, percentage drug entrapment efficiency, in vitro drug release. FT-IR drug-excipient compatibility studies were revealed that there was no interaction between drug and selected lipids. The particle size ranged from 192.7 to 359.5 nm, PDI of all formulations were good within the range of 0.432 to 1.000, zeta potential ranged from -3.25 mV to -26.7 mV, Percentage drug entrapment efficiency of all formulations were observed were in the range of 78.88% to 93.67%. The cumulative percentage release of Ketotifen Fumarate from different formulations varied from 76.61% to 93.88%. Among all formulations, the formulation F1 showed highest drug release of 93.88% and considered as optimized formulation. The release kinetic studies showed that the release was first order (R2=0.956) diffusion controlled and the ‘n’ value obtained from the Korsmeyer-Peppas model indicated the release mechanism was Anomalous diffusion (non-fickian type) (n-value of F1 was 0.613). The developed SLNs were able to sustain the drug release for 12 hrs.